Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia

Abstract

Knowledge regarding the association between hypofibrinogenemia and tigecycline is based mainly on case reports. However, the clinical features of tigecycline-induced hypofibrinogenemia are unclear. We collected 20 patients (16 males and 4 females) with tigecycline-induced hypofibrinogenemia by searching the Chinese and English databases from June 2005 to May 2021, with a median age of 63.5 years (range 39∼90 years). Hypofibrinogenemia developed at a median of 9 days (range 2∼35 days). Most patients had no typical clinical manifestations, and only a few patients had bleeding and ecchymosis. Fibrinogen levels gradually decreased from 3.98 ± 2.05 g/L to 0.87 ± 0.45 g/L (P = 0.000), and the activated partial thromboplastin time (APTT) increased from 38.26 ± 8.80 s to 83.43 ± 47.23 s (P = 0.002). Fibrinogen levels in all patients recovered to the normal range within a median of 4 days (range 1∼12 days) after tigecycline cessation. Our results suggest that fibrinogen levels should be closely monitored in patients treated with tigecycline, specifically patients who may have renal insufficiency or patients with long-term use.

Keywords:

• Tigecycline
• hypofibrinogenemia
• fibrinogen
• coagulopathy
• adverse reaction

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethical statement

This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.

Author contributions

Conception and design: Chunjiang Wang and Haibo Lei. Writing, review, and revision of the manuscript: Chunjiang Wang, Xiang Liu, Zuojun Li and Haibo Lei. All authors read and approved the current version of the manuscript.

Additional information

Funding

This study was funded by the Natural Science Foundation of Hunan Province (No.2021JJ80083).